Cabaletta Bio (CABA) vs Zura Bio (ZURA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 11, 2026.
Summary
Zura Bio (ZURA) has outperformed Cabaletta Bio (CABA) over the past year, losing 3.6% versus a loss of 16.8%. Zura Bio is the larger company by market cap ($383.3 million vs $327.2 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CABA | ZURA |
|---|---|---|
| Share price | $1.93 | $4.00 |
| Market cap | $327.22M | $383.32M |
| 1-day change | -1.03% | -3.15% |
| YTD return | -11.87% | -23.66% |
| 1-year return | -16.81% | -3.61% |
| 5-year return | -84.26% | — |
| EPS (TTM) | $-1.51 | $-1.12 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.23 | $7.44 |
| 52-week low | $1.83 | $3.15 |
| Distance from 52-week high | -54.37% | -46.24% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +586.53% | +350.00% |
| Average volume | 4.61M | 1.44M |
| Shares outstanding | 169.55M | 95.83M |
| Employees | 154 | 40 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ZURA has outperformed CABA by 13.2 percentage points over the past year.
About Cabaletta Bio
CABA stock →Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases. The company's lead product candidate is resecabtagene autoleucel, a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T, which is in Phase 1/2 clinical trials for the treatment of dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, juvenile myositis, lupus nephritis, systemic lupus erythematosus, relapsing and progressive multiple sclerosis, mucocutaneous and mucosal pemphigus vulgaris (PV), systemic sclerosis, and generalized myasthenia gravis.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 154 employees
About Zura Bio
ZURA stock →Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for autoimmune and inflammatory disorders in the United States. The company develops Tibulizumab, a humanized IgG4 single-chain variable fragment bispecific antibody engineered to bind and neutralize both IL-17A and BAFF within a single therapeutic molecule, which is in Phase 2 clinical trial development.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 40 employees
CABA vs ZURA FAQ
Which is bigger, Cabaletta Bio or Zura Bio?
Zura Bio (ZURA) is larger, with a market capitalization of $383.32M compared with $327.22M for Cabaletta Bio (CABA).
Which stock has performed better over the past year, CABA or ZURA?
ZURA returned -3.61% over the past 12 months, compared with -16.81% for CABA (price return, excluding dividends). Past performance does not predict future results.
Are Cabaletta Bio and Zura Bio in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.